Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 1
2002 2
2003 2
2011 1
2012 1
2015 1
2016 1
2018 1
2019 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH, Suthoff E, Jain R, Kosinski M, Fridman M, Deligiannidis KM, Meltzer-Brody S, Chen SY, Gervitz L, Huang MY, Trivedi M, Bonthapally V. Clayton AH, et al. Among authors: gervitz l. J Affect Disord. 2024 Apr 15;351:904-914. doi: 10.1016/j.jad.2024.01.268. Epub 2024 Feb 5. J Affect Disord. 2024. PMID: 38325605 Free article. Clinical Trial.
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC. Burmester GR, et al. Among authors: gervitz l. RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019. RMD Open. 2019. PMID: 31673415 Free PMC article. Clinical Trial.
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
van der Heijde D, Keystone EC, Curtis JR, Landewé RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE. van der Heijde D, et al. Among authors: gervitz lm. J Rheumatol. 2012 Jul;39(7):1326-33. doi: 10.3899/jrheum.111171. Epub 2012 May 15. J Rheumatol. 2012. PMID: 22589265 Clinical Trial.
14 results